Clincosm LogoSign in Get a demo

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00142155
Collaborator
(none)
300
Enrollment
1
Location
61.9
Duration (Months)
4.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

  • A medical data collection survey sheet will be filled out by the patient or doctor with medical information pertaining to how the patient responded to rituximab and other monoclonal antibodies for use in this study.

  • Blood work will be performed to analyze the blood by molecular technology to find the kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with the outcome of treatment with rituximab or other monoclonal antibodies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Official Title:
Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia
Study Start Date :
Jan 1, 2002
Actual Primary Completion Date :
Mar 1, 2007
Actual Study Completion Date :
Mar 1, 2007

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's macroglobulinemia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dana-Farber Cancer Institute Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Dana-Farber Cancer Institute

    Investigators

    • Principal Investigator: Steven Treon, MD, MA, PhD, Dana-Farber Cancer Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00142155
    Other Study ID Numbers:
    • 02-075
    First Posted:
    Sep 2, 2005
    Last Update Posted:
    Jun 27, 2011
    Last Verified:
    Jun 1, 2011
    Keywords provided by , ,
    monoclonal antibody
    Fc gamma RIII receptor expression
    rituximab
    Additional relevant MeSH terms:
    Waldenstrom Macroglobulinemia
    Rituximab
    Antibodies
    Antibodies, Monoclonal

    Study Results

    No Results Posted as of Jun 27, 2011